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Abstract
The advent of Immune Checkpoint Inhibitors (ICIs) as a standard of care for several
cancers, including melanoma and head/neck squamous cell carcinoma has changed
the therapeutic approach to these conditions, drawing at the same time the attention
on some safety issues related to their use. To assess the incidence of psoriasis as a
specific immune-related cutaneous adverse event attributing to ICIs using the
Eudravigilance reporting system. All reports of adverse drug reactions (ADRs) con-
cerning either exacerbation of psoriasis or de novo onset of psoriasis/psoriasiform
reactions associated to the use of Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4)
inhibitors ipilimumab and tremelimumab, and the Programmed cell Death protein
1/Programmed Death-Ligand 1 (PD-1/PD-L1) inhibitors nivolumab, pembrolizumab,
atezolizumab, durvalumab, avelumab, and cemiplimab were identified and extracted
from the Eudravigilance reporting system, during the period between the date of
market licensing (for each study drug) and 30 October 2020. 8213 reports of cutane-
ous ADRs associated with at least one of study drug have been recorded, of which
315 (3.8%) reporting psoriasis and/or psoriasiform reactions as ADR. In 70.8% of
reports patients had pre-existing disease. ICIs-related skin toxicity is a well-
established phenomenon, presenting with several conditions, sustained by an
immune background based on the activity of some cells (CD4+/CD8+ T-cells, neutro-
phils, eosinophils, and plasmocytes), inflammatory mediators, chemokines, and
tumor-specific antibodies. In this setting, psoriasis represents probably the most par-
adigmatic model of these reactions, thus requiring adequate recognition as no guide-
lines on management are now available.
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1 | INTRODUCTION
Immune Checkpoints Inhibitors (ICIs) represent a new group of mono-
clonal antibodies that proved to be effective on several malignancies
by blocking specific targets such as Cytotoxic T-Lymphocyte
Antigen-4 (CTLA-4) and Programmed cell Death protein 1 (PD-1)/
Programmed Death-Ligand 1 (PD-L1).1
ICIs are characterized by a common pathway of action. They
cause cytotoxic T-cell activation and enhance tumor cells
destruction.2,3Gianluca Trifirò and Claudio Guarneri have contributed equally to this study.
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Along with tremelimumab, ipilimumab is a recombinant human
monoclonal IgG1 antibody acting against CTLA-4, a protein expressed
in activated T cells. As CTLA-4 promotes inhibition of the immune
response, the net action of these two drugs consists in the increasing
activation and proliferation of T-lymphocytes by blocking the interac-
tion of CTLA-4 with its ligands CD80 and CD86. Since 2011,
ipilimumab was approved for the treatment of unresectable or meta-
static melanoma and renal cell carcinoma.4
Nivolumab and pembrolizumab have been approved as mon-
otherapy or in combination with other drugs for the treatment of mel-
anoma, head and neck squamous cell carcinoma, renal cell carcinoma,
lung cancer (small cell and nonsmall cell types), and other neo-
plasms.5-8 They are human monoclonal IgG4 antibodies targeting the
PD-1 receptor, which promotes the activity of specific T-lymphocytes
both in peripheral and tumor tissues.
Atezolizumab, durvalumab, and avelumab are PD-L1 protein
inhibitors that have been recently approved in Italy for the treatment
of metastatic nonsmall-cell lung cancer, locally advanced or metastatic
urothelial carcinoma, extensive-stage small-cell lung cancer, and meta-
static Merkel cell carcinoma.9,10 Cemiplimab has been authorized as
monotherapy for the treatment of adult patients with metastatic or
locally advanced cutaneous squamous cell carcinoma (mCSCC or
laCSCC), who are not candidates for curative surgery or radiation
(Table 1).
Because of the wide and growing use of these products, relevant
safety concerns are emerging during the last years. Based on the
potential effect on the immune response and the available evidence
coming from randomized clinical trials, registries and medical literature
reports, more than 60% of patients treated with ICIs develop several
adverse effects, affecting a lot of body systems.11-14
TABLE 1 Date of marketing authorization and description of approved therapeutic indications for the immune checkpoint inhibitors included
in the study
ICI Target Date of EMA approval Therapeutic indications approved by EMA
Ipilimumab CTLA-4 07/2011 • Metastatic or unresectable melanoma
• Advanced renal cell carcinoma
• Nonsmall cell lung cancer (NSCLC)/metastatic
NSCLC
Nivolumab PD-1 06/2015 • Metastatic or unresectable melanoma (also with
ipilimumab)
• Nonsmall cell lung cancer (NSCLC)
• Advanced renal cell carcinoma
• Classical Hodgkin lymphoma
• Recurrent or metastatic squamous cell carcinoma of
the head and neck (SCCHN);
• Locally advanced or metastatic urothelial carcinoma
Pembrolizumab PD-1 07/2015 • Metastatic or unresectable melanoma
• Nonsmall cell lung cancer (NSCLC
• Classical Hodgkin lymphoma
• Locally advanced or metastatic urothelial carcinoma
• Recurrent or metastatic head and neck squamous
cell carcinoma (HNSCC),
• Renal cell carcinoma
Atezolizumab PD-L1 09/2017 • Locally advanced or metastatic urothelial carcinoma
• Metastatic nonsmall cell lung cancer (NSCLC)
• Extensive -stage small cell lung cancer (ES-SCLC)
• Triple-negative breast cancer
Avelumab PD-L1 09/2017 • Metastatic Merkel cell carcinoma
• Advanced renal cell carcinoma (plus axitinib)
Durvalumab PD-L1 09/2018 • Locally advanced, unresectable nonsmall cell lung
cancer (NSCLC)
• Extensive-stage small cell lung cancer (ES-SCLC) (in
combination with etoposide and either carboplatin
or cisplatin)
Cemiplimab PD-1 06/2019 • Locally advanced or metastatic cutaneous
squamous cell carcinoma
Tremelimumab CTLA-4 07/2019 • Malignant neoplasms (excluding central nervous
system, hematopoietic and lymphoid tissue
neoplasms)
• Malignant neoplasms of hematopoietic and
lymphoid tissue
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Concerning the skin, more than 30% of reports are characterized
by mild cutaneous toxicity, alone or associated with other symp-
toms.14 A possible etiopathogenic explanation of these “specific”
reactions is the overall stimulation of the immune system against the
tumor cells induced by ICIs. Indeed, inhibition of CTLA-4 promotes
CD4+ and CD8+ function as well as PD-1 and PD-1 ligands are
expressed in immune cells including activated T lymphocytes, B lym-
phocytes, dendritic cells, and macrophages. Although it has been not
yet fully elucidated, the above-mentioned drugs could act as a trigger
of autoimmunity, particularly at the skin level.1,2,13,14,15
Several skin conditions have been associated with ICIs, including
alopecia areata, vitiligo, pyoderma gangrenosum, erythema nodosum,
prurigo nodularis, Sweet's syndrome, Sjogren syndrome, dermatomyo-
sitis, sarcoidosis, lichen, and psoriasis, but also urticaria, rosacea,
rashes, and pruritus.13,16,17
Chronic plaque psoriasis or other clinical phenotypes
(erythrodermic, pustular, guttate, palmoplantar, scalp/nail, and inverse
psoriasis) have been attributed to ICI treatment, as a recrudescence of
an existing disease or as a new-onset form.18,19 According with the
pathogenesis of psoriasis, PD-1 inhibition could strongly impact the
Th1/Th17 pathways, leading to IL-17 overexpression and to the typi-
cal inflammatory cascade with the antitumor activity.20-22
The purpose of this paper is to briefly review ICI-related reports
from the Eudravigilance reporting system during the period 2011 to
2020 concerning with psoriasis and psoriatic adverse drug reactions
and to better characterize the incidence of this skin toxicities, thus
providing recommendations for their management.
2 | METHODS
For our research, we used the public version of Eudravigilance data-
base (http://www.adrreports.eu/en/search.html). This website was
founded by the European Medicines Agency (EMA) in 2012 to pro-
vide public access to reports of suspected side effects/adverse drug
reactions. These reports are submitted electronically by national medi-
cines regulatory authorities and by pharmaceutical companies that
hold marketing licenses for the medicines.
All cutaneous ADR reports related to ipilimumab, tremelimumab,
nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab and
cemiplimab particularly if manifesting as psoriasis or psoriasiform der-
matitis, were considered since their market authorization by EMA to
30 October 2020. According with the website searching options, we
selected “suspected adverse drug reaction reports for substances”
then browsing the name of each of the drugs and MedDRA PT term
“psoriasis” among “Skin and subcutaneous tissue disorders”. Further-
more, line-listing including more clinical data about selected ADR
reports were examined in detail.
The data were collected with no limitation for seriousness of the
reaction, geographic origin, sex or age group of the patients.
Tremelimumab was approved for use only in the second half of
2019 and no psoriasis/psoriasiform ADRs are still available in the
database. Similarly, cemiplimab has been marketed in 2019 and only
two cases were documented in Eudravigilance. Durvalumab,
atezolizumab and avelumab were licensed between the late 2017 and
the end of 2018 and few reports of such reactions have been
reported. The main part of psoriatic ADRs were related to nivolumab
and pembrolizumab, with few cases on ipilimumab (Table 1).
3 | RESULTS
Overall, 8213 ADR reports regarding skin and subcutaneous tissue
disorders associated with ICIs were collected in the EudraVigilance
reporting system during the study period. Of these, 315 (3.8%)
reported psoriasis as ICI-related ADR, occurring de novo or as a recur-
rence in previously diagnosed patients.
ICI-related psoriasis reports more frequently concern males
(234 out of 307; 75.9%) in the age range 65 to 85 years (145 out of
217; 66.3%). In the majority of reports in which such clinical data are
available (N = 118; 70.2%) psoriasis presents more as a new flare in
patients with pre-existing disease than as a new-onset disease and
patients were mainly treated with topical steroids for these adverse
reactions (102 out of 138; 73.9%).
With regard to the type and seriousness of the psoriatic adverse
reactions there are no detailed information available in the reporting
system. The outcome was “unknown” in 124 cases (39.3%) whereas a
total of 138 (44.1%) of cases were generally considered “recovered/
resolved” (N = 60) or “recovering/resolving” (N = 78); only two cases
(0.6%) were resolved “with sequelae” while N = 51 cases (16%) were
“not recovered/not resolved.”
Among individual compounds, the most frequently reported ICI
was nivolumab (N = 175; 55.9%), followed by pembrolizumab
(N = 104; 33.2%), atezolizumab (N = 15; 4.8%), ipilimumab (N = 12;
3.8%), cemiplimab (N = 2; 0.6%), and avelumab (N = 1; 0.3%). In N = 7
reports nivolumab and ipilimumab were co-administered.
Psoriasis represents only the 0.8% (12 out of 1476) of the total
number of cutaneous ADRs associated to ipilimumab and 2.9% of
those associated to avelumab (only one case report out of 34), vs
3.7% (6 out of 160) with durvalumab, 4.1% (104 out of 2532) with
pembrolizumab, 4.4% (145 out of 341) with atezolizumab, 4.8% with
nivolumab (175 out of 3668), and 4.9% (two out of 41) with
cemiplimab.
Except for durvalumab related-psoriasis, affecting four females
out of six patients, this adverse reaction occurs mainly in males (with
percentages ranging from 71.1% observed for pembrolizumab to
83.3% observed for ipilimumab).
ICI related-psoriasis affected more frequently older people than
other cutaneous ADRs: 66.4% in the 65/85 years group vs 54.6% of
other cutaneous ADRs.
4 | DISCUSSION
Skin is the most common organ affected by ADRs under pharmaco-
logical treatments, even more true when the drug targets
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immunological checkpoints.23 Using ICIs, the occurrence of adverse
events, although it has not fully established, may correlate with the
antitumor immune response.5
The two classes of immunotherapeutic agents (CTLA-4 and
PD1-receptor/ligand inhibitors) recognize different molecular targets
but show similar cutaneous side effects, represented by different
types of maculopapular rashes with varying severity, itching, mucosal
toxicity, vitiligo and lichenoid reactions, occurring in more than 30%
of patients on ICI.24-26
Psoriasis is a chronic, immune-mediated, multifaced inflammatory
skin disease having a high physical and psychosocial impact into
patients' life, the estimated prevalence of which, ranging from 0.27 to
11.4% worldwide, makes the disease common.27
Psoriasis is also common as ADR, but its real incidence in course
of ICIs has been not exactly estimated; several reports and case series
have been published in the last years.28,29
A literature review, linked to a case presentation, was recently
proposed by De Bock et al.18 They checked a total of 35 cases of pso-
riasis flared during ICI therapy, now representing the largest database
on this topic. According to their data, the majority of events occurred
as an exacerbation of a pre-existing disease, although five reports of
new onset psoriasis were reported.
The overall median time for the onset of cutaneous lesions was
31 days (mean 50.1 days), while exacerbation occurred at 28.5 days in
patients with established psoriasis and at 59 days in those with de
novo presentation. Management included extensive using of topical
and systemic corticosteroids together with topical Vitamin D ana-
logues/betamethasone compounds, UVB phototherapy, oral Acitretin,
and Methotrexate whereas treatment with ICI was interrupted in nine
patients. The authors concluded that, as psoriasis eruption is a possi-
ble ADR in course of ICIs, reliable epidemiologic data are needing for
an optimal care of these patients.
In 2019, Coleman et al carried out a single-institution retrospec-
tive analysis focused on the inflammatory skin eruptions associated
with ICI therapy. In their cohort a total of 98 patients (51 men,
47 women) and 103 skin eruptions were included, 17 of which (17%,
eight men and nine women, mean age 67 years) having psoriasiform
reactions. Only in a single case it was attributed to a CTLA-4 inhibitor,
while in 12 it was caused by an anti-PD1/PD-L1 and in four by their
association. The reported latency period was 5.7 months (range
0.2-28.8), with generally low severity events. With regard to the type
of psoriasis, the main part was represented by classical chronic plaque
or scalp psoriasis, with two inverse and two palmoplantar pustular
forms; in one case also psoriatic arthritis was detected.30
To the best of our knowledge, our study is the first that collected
ICIs-related ADR reports using the European Medicine Agency data-
base (EudraVigilance).31 We summarized 8213 cutaneous ADR occur-
ring with using CTLA-4 inhibitors ipilimumab (n = 1476) and the PD-
1/PD-1 ligand inhibitors nivolumab (n = 3668), pembrolizumab
(n = 2532), atezolizumab (n = 341), avelumab (n = 34), and
durvalumab (n = 160).
Among these events, we firstly reported a prevalence rate of
3.81% of psoriasis or psoriasiform manifestations, based on a cohort
of 313 patients/cases, that represents the largest actually available
in medical literature. This data is significantly different from the one
presented by Coleman et al31 (17%); however, it might be partly
explained by the fact that they considered only inflammatory erup-
tions developed in course of ICIs. Within a sub-analysis of our data,
we noted that this percentage is significantly lower in patients
treated with CTLA-4 inhibitors (0.8% on ipilimumab, no available
reports regarding tremelimumab), that is coherent with other stud-
ies, than in course of PD-1/PD-1 ligand inhibitors. As cutaneous
eruptions have been reported in literature to be more common on
CTLA-4 inhibitors than anti PD-1/PD-L1 inhibitors,26,31 according
with the extracted data we suggest that this may be not valid for
psoriasis. This opposite effect should be supposed to be due to the
different molecular target, but the exact mechanism has to be
demonstrated.
Psoriasis and psoriasiform dermatitis are generally not serious
adverse events. In our analysis, only in six cases (1.9%) immunother-
apy was discontinued because of skin disease (generalized pustular
dermatitis has been reported in two cases), being temporarily inter-
rupted in 43 (13.7%). Similarly, Coleman et al. reported no discontinu-
ation of immunotherapy, with interruption in only one out of their
17 cases (5.9%), whereas the review of literature by de Bock et al rev-
ealed discontinuation of anti-cancer treatment in two cases (5.7%)
and temporary interruption in five cases (14.3%).18,30
Psoriasis flares were treated with either topic and systemic older
drugs or newer biotechnological options, depending on the serious-
ness of manifestations. Because of the underlying malignant condi-
tions, the possible causal drugs have not been always suspended
whereas cyclosporine and novel biologic agents have been avoided in
the majority of cases. More recently, apremilast, the PDE-4 inhibitor
that has been licensed for the treatment of psoriasis and psoriatic
arthritis in neoplastic patients, has been also used.
In our study, we found 145 patients (46.3%) that were treated
with topical agents, including mainly steroids or combination of ste-
roids with vitamin D analogues, and 24 (7.7%) treated with photother-
apy; 10 patients (3,2%) required systemic treatment, 18 (5.7%) of
which treated with systemic steroids, two with acitretin, one with
cyclosporine, one with methotrexate, one with efalizumab, two with
etanercept, and three with apremilast. Curiously, traditional and
newer systemic antipsoriatic agents have been used only in patients
on nivolumab (7) and pembrolizumab (3).
The other above mentioned two studies showed similar results.
5 | CONCLUSION
Skin toxicity represents a well-established phenomenon in course of
CTLA-4 and PD-1/PDL-1 checkpoint inhibitors. Knowledge, early rec-
ognition and proper management of related conditions is mandatory
in using these drugs and availability of data on these ADRs
desirable.32
In this setting, psoriasis and psoriatic manifestations have been
largely described as immune-related reactions.
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As the literature is rich of single case presentations or small series,
we accessed the ADR database of the European Medicines Agency to
summarize the available reports and provide an overview on the topic.
Some limitations characterized our study. First of all,
Eudravigilance collects all spontaneous reports on suspected ADRs
sent by consumers and every kind of healthcare professionals, so,
from a strictly dermatological point of view, there is a lack of useful
information on the clinical features and course of the specific condi-
tion. In particular, through this data analysis is impossible to evaluate
the time to onset of this ADR, the type and extent of psoriasis
(in terms of PASI or BSA) and the presence of other related com-
orbidities, with not relevant information on concomitant therapies
except for coadministered antineoplastic drugs.
This reflects the fact that the existing grading system of toxicities
should not be applied to cutaneous reactions, that need several details
to be appropriately assessed and managed.
In conclusion, the analysis of spontaneous ADR reports on ICIs
confirmed the well-known risk associated with this drug class at the
skin level, especially systemic immune-related effects.
The awareness of dermatologic toxicity to immune checkpoint
blockade will become even more critical for patient care in the future,
in view of the growing use of these antineoplastic agents.
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